| sRAI +  (n = 140) | D1SCr > Baseline +  (n = 253) | p-value sRAI + vs. D1SCr +  | RAI +  (n = 195) | p-value sRAI + vs. RAI +  |
---|---|---|---|---|---|
D3 Severe AKI, n (%) | 67 (48) | 71 (28) |  < 0.001 | 76 (39) | 0.11 |
RR vs. D1 SCr > Baseline +  | RR 1.7 (1.3–2.2) | – |  < 0.001 | – | – |
RR vs. RAI +  | RR 1.2 (0.96–1.6) | – | – | – | 0.11 |
D3 Severe AKI Prediction | |||||
AUROC | 0.86 (0.82–0.90) | 0.82 (0.76–0.88) | 0.19 | 0.86 (0.82–0.90) | – |
Sensitivity, % | 85 (75–92) | 90 (81–95) |  | 96 (89–99) | |
Specificity, % | 74 (69–79) | 36 (30–42) |  | 58 (52–64) | |
PPV, % | 48 (39–56) | 28 (23–34) |  | 39 (32–46) | |
NPV, % | 95 (91–97) | 93 (86–97) |  | 98 (94–99) | |
 + LR | 3.3 (2.7–4.1) | 1.4 (1.3–1.6) |  | 2.3 (2.0–2.7) | |
-LR | 0.2 (0.1–0.4) | 0.28 (0.1–0.6) |  | 0.07 (0.02–0.2) | |
D1-7 KRT Use. n (%) | 45 (32) | 42 (12) |  < 0.001 | 46 (24) | 0.08 |
RR vs. D1 SCr > Baseline +  | RR 1.9 (1.3–2.8) | – |  < 0.001 | – | – |
RR vs. RAI +  | RR 1.4 (0.96–1.9) | – | – | – | 0.08 |
PICU Free Days | 14.5 (0–23) | 23 (11–26) |  < 0.001 | 18 (0,24) | 0.15 |
28-day Mortality, n (%) | 16 (11) | 18 (7) | 0.15 | 20 (10) | 0.73 |
RR vs. D1 SCr > Baseline +  | RR 1.6 (0.8–3) | – | 0.15 | – | – |
RR vs. RAI +  | RR 1.1 (0.6–2.1) | – | – | – | 0.73 |